Literature DB >> 21314815

The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands.

Jun Miyazaki1, Koji Kawai, Takahiro Kojima, Takehiro Oikawa, Akira Joraku, Toru Shimazui, Akihiro Nakaya, Ikuya Yano, Takashi Nakamura, Hideyoshi Harashima, Hideyuki Akaza.   

Abstract

OBJECTIVE: • To conduct a preclinical evaluation of the ability of natural killer cells to cytolyze bladder cancer cells that were modified to show enhanced expression of natural-killer group 2, member D (NKG2D) ligands by R8-liposome-bacillus Calmette-Guéin (BCG)-cell wall skeleton (CWS) treatment.
MATERIALS AND METHODS: • The T24 cells and RT-112 cells were co-cultured with R8-liposome-BCG-CWS and BCG for 2, 4, or 6 h, and then the surface expression of NKG2D ligands was analyzed using TaqMan real-time quantitative RT-PCR. • Peripheral blood mononuclear cells were obtained with a conventional preparation kit, and then lymphokine-activated killer (LAK) cells were generated from these purified peripheral blood mononuclear cells via interleukin-2 stimulation. • The anti-tumour effect of LAK cells against untreated and R8-liposome-BCG-CWS co-cultured with cells of the human bladder cancer cell lines T24 and RT-112 was analyzed using the cytotoxic WST-8 assay method at 4 h of culture at various effector/target (E : T) ratios.
RESULTS: • Major histocompatibility complex class I-related chain B (MICB) expression was increased ≈1.5-fold on T24 cells and RT-112 cells with BCG. • UL-16-binding protein (ULBP) 1 expression was also increased ≈1.5-fold on T24 cells and RT-112 cells with BCG. R8-liposome-BCG-CWS increased the surface expression of MICB 2.2-fold on T24 cells but did not increase it significantly on RT-112 cells. • ULBP1 expression was increased ≈2.2-fold on RT-112 cells, although no differences were observed between the expression of ULBP2 and 3 with R8-liposome-BCG-CWS. • T24 cells that were co-cultured with R8-liposome-BCG-CWS showed an ≈1.3-fold increase in sensitivity to cytolysis by LAK cells at an E : T ratio of 4 and RT-112 cells showed an ≈1.4-fold increase at an E : T ratio of 2.
CONCLUSIONS: • In the present study, the induction of surface NKG2D ligands by R8-liposome-BCG-CWS rendered cancer cells more susceptible to cytolysis by LAK cells. • T24 cells and RT-112 cells, even when cultured singly in the absence of immune cells, can directly respond to R8-liposome-BCG-CWS. • The results obtained in the present study may therefore indicate a novel adoptive immunotherapy against bladder cancers.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21314815     DOI: 10.1111/j.1464-410X.2010.10056.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review).

Authors:  Michael D Weintraub; Qingdi Quentin Li; Piyush K Agarwal
Journal:  Mol Clin Oncol       Date:  2014-06-12

Review 2.  Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.

Authors:  Koji Kawai; Jun Miyazaki; Akira Joraku; Hiroyuki Nishiyama; Hideyuki Akaza
Journal:  Cancer Sci       Date:  2013-01-03       Impact factor: 6.716

3.  Cell-Penetrating Peptide and Transferrin Co-Modified Liposomes for Targeted Therapy of Glioma.

Authors:  Xi Wang; Yarong Zhao; Shiyan Dong; Robert J Lee; Dongsheng Yang; Huan Zhang; Lesheng Teng
Journal:  Molecules       Date:  2019-09-30       Impact factor: 4.927

4.  Liposome-Encapsulated Bacillus Calmette-Guérin Cell Wall Skeleton Enhances Antitumor Efficiency for Bladder Cancer In Vitro and In Vivo via Induction of AMP-Activated Protein Kinase.

Authors:  Young Mi Whang; Da Hyeon Yoon; Gwang Yong Hwang; Hoyub Yoon; Serk In Park; Young Wook Choi; In Ho Chang
Journal:  Cancers (Basel)       Date:  2020-12-08       Impact factor: 6.639

5.  Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy.

Authors:  Mark Bazett; Amanda M Costa; Momir Bosiljcic; Rebecca M Anderson; Matthew P Alexander; Stephanie W Y Wong; Salim Dhanji; Jenny Mh Chen; Jim Pankovich; Stephen Lam; Simon Sutcliffe; Hal Gunn; Shirin Kalyan; David W Mullins
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

Review 6.  Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer.

Authors:  Julieti Huch Buss; Karine Rech Begnini; Camila Bonemann Bender; Adriana R Pohlmann; Silvia S Guterres; Tiago Collares; Fabiana Kömmling Seixas
Journal:  Front Pharmacol       Date:  2018-01-12       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.